Tango Therapeutics Inc
TNGXHealthcare|Biotechnology|USA
$31.06
+0.52 (+1.71%)
Tangible Book
$2.72
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06188702 S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP | MTAP-deleted Solid Tumors | P1P2 | Active | 60 | Open-label | S095035, TNG462 |
| NCT06810544 Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme | P1P2 | Recruiting | 191 | Open-label | TNG456, abemaciclib |
| NCT05887492 Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Non Small Cell Lung Cancer, Solid Tumors, Adult | P1P2 | Active | 126 | Open-label | TNG260, Pembrolizumab |
| NCT06922591 Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | P1P2 | Recruiting | 183 | Open-label | TNG462, RMC-9805, RMC-6236, mFOLFIRINOX, gemcitabine/nab-paclitaxel |
| NCT05732831 Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Locally Advanced Solid Tumor | P1P2 | Recruiting | 225 | Open-label | TNG462, Pembrolizumab |
| NCT05275478 Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | Locally Advanced Solid Tumor | P1P2 | Terminated | 110 | Open-label | TNG908 |
| NCT06065059 Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors | Breast Cancer, Ovarian Cancer | P1P2 | Terminated | 7 | Open-label | TNG348, Olaparib |